此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

特发性肺纤维化和间质性肺病前瞻性结果登记 (IPF/ILD-PRO)

2026年11月9日 更新者:Duke University

特发性肺纤维化前瞻性结果 (IPF-PRO) 和慢性纤维化间质性肺病进展性表型前瞻性结果 (IPF-PRO/ILD-PRO) 注册

The Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry started recruiting in 2014 with the objective of studying Idiopathic Pulmonary Fibrosis. In 2018, the registry expanded to include recruitment of participants with other chronic fibrosing interstitial lung diseases (ILDs) with progressive phenotype also referred to as progressive fibrosing interstitial lung diseases in the Chronic Fibrosis Interstitial Lung Disease with Progressive Phenotype (ILD-PRO) Registry. When the third phase of the registry begins, the IPF-PRO registry will enroll additional patients with idiopathic pulmonary fibrosis. This IPF-PRO registry is a prospective registry that will collect information regarding the natural history, health care interactions, participant reported questionnaire data to assess quality of life, and the methods of treatment of participants with a diagnosis of idiopathic pulmonary fibrosis (IPF) or of another chronic fibrosing interstitial lung disease (ILD) with progressive phenotype established at the enrolling centers. In addition, blood samples and chest image studies will be collected and banked for future research projects.

研究概览

地位

招聘中

详细说明

This registry originally enrolled a total of 1002 participants newly diagnosed with IPF and continues to enroll patients with other chronic fibrosing ILDs with newly identified progressive phenotype to reach an enrollment of 1000 patients. Participants will be enrolled in three phases, (IPF-PRO and ILD-PRO) over a span of 8 years at approximately 50 sites experienced in the diagnosis and treatment of ILD in the United States. Enrollment for the original IPF cohort started in 2014 and ended in October 2018, with 1002 total participants enrolled. In the third phase of the registry new enrollment for patients with IPF will restart in 2023-2024 with the plan to enroll up to 1000 new IPF patients, for a total IPF enrollment of 2000. Enrollment for other chronic fibrosing ILDs with newly identified progressive phenotype cohort was initiated in February 2019 and will end when enrollment reaches 1000 participants with the potential of enrolling another 1000 participants with other chronic fibrosing ILDs with newly identified without a progressive phenotype. Data and samples will be collected from participants for approximately 5 years for the IPF cohort. For the chronic fibrosing ILD with progressive phenotype cohort, data and samples will be collected for a minimum of 3 years, up to approximately 5 years. Participant management and treatment decisions will be determined by participants and their health care professionals.

研究类型

观察性的

注册 (估计的)

3000

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

    • Alabama
      • Birmingham、Alabama、美国、35294
        • 招聘中
        • University of Alabama - Birmingham
        • 首席研究员:
          • Tejaswini Kulkarni, MD
        • 接触:
    • Arizona
      • Tucson、Arizona、美国、85721
        • 招聘中
        • University of Arizona
        • 首席研究员:
          • Sally A Suliman, MD
        • 接触:
    • California
      • Los Angeles、California、美国、90033
        • 招聘中
        • University of Southern California
        • 接触:
        • 首席研究员:
          • Toby Maher, MD
      • Los Angeles、California、美国、90024
        • 招聘中
        • University of California - Los Angeles
        • 首席研究员:
          • John Belperio, MD
        • 接触:
      • Stanford、California、美国、94305
        • 招聘中
        • Stanford University
        • 首席研究员:
          • Rishi Raj, MD
        • 接触:
    • Colorado
      • Aurora、Colorado、美国、80045
        • 招聘中
        • University of Colorado
        • 首席研究员:
          • Joyce Lee, MD
        • 接触:
    • Connecticut
      • New Haven、Connecticut、美国、06520
        • 招聘中
        • Yale University
        • 首席研究员:
          • Mridu Gulati, MD
        • 接触:
    • Florida
      • Gainesville、Florida、美国、32610-3175
      • Tampa、Florida、美国、33606
        • 招聘中
        • University of South Florida
        • 首席研究员:
          • Jose D Herazo-Maya, MD
        • 接触:
    • Georgia
      • Atlanta、Georgia、美国、30322
        • 招聘中
        • Emory University
        • 接触:
        • 首席研究员:
          • Srihari Veeraraghavan, MD
      • Austell、Georgia、美国、30106
        • 招聘中
        • Piedmont Healthcare
        • 首席研究员:
          • Amy Case, MD
        • 接触:
    • Illinois
      • Chicago、Illinois、美国、60637
        • 招聘中
        • University of Chicago
        • 首席研究员:
          • Mary Strek, MD
        • 接触:
      • Evanston、Illinois、美国、60611
        • 招聘中
        • Northwestern University
        • 接触:
        • 首席研究员:
          • Bradford Bemiss, MD
      • Maywood、Illinois、美国、60153
        • 招聘中
        • Loyola University Health System
        • 首席研究员:
          • Daniel Dilling, MD
        • 接触:
    • Kansas
      • Kansas City、Kansas、美国、66160
        • 终止
        • University of Kansas
    • Kentucky
      • Lexington、Kentucky、美国、40536
        • 招聘中
        • University of Kentucky
        • 首席研究员:
          • Girish Nair, MD
        • 接触:
    • Louisiana
      • New Orleans、Louisiana、美国、70112
        • 招聘中
        • Tulane University
        • 首席研究员:
          • Joe Lasky, MD
        • 接触:
    • Michigan
      • Ann Arbor、Michigan、美国、48109
        • 主动,不招人
        • University of Michigan
      • Detroit、Michigan、美国、48202
        • 招聘中
        • Henry Ford Health
        • 接触:
        • 首席研究员:
          • Asif Abdul Hameed, MD
    • Minnesota
      • Minneapolis、Minnesota、美国、55455
        • 招聘中
        • University of Minnesota
        • 接触:
        • 首席研究员:
          • Hyum Kim, MD
    • Mississippi
      • Jackson、Mississippi、美国、39216
        • 招聘中
        • University of Mississippi Medical Center
        • 首席研究员:
          • Kimberly Dobbs, MD
        • 接触:
    • Missouri
      • St Louis、Missouri、美国、63110
        • 招聘中
        • Washington University
        • 首席研究员:
          • Tonya Russell, MD
        • 接触:
    • New York
      • New York、New York、美国、10065
        • 招聘中
        • Weill Medical College of Cornell University
        • 首席研究员:
          • Kerri Aronson, MD
        • 接触:
      • New York、New York、美国、10016
        • 主动,不招人
        • NYU Medical Center
    • North Carolina
      • Chapel Hill、North Carolina、美国、27514
      • Durham、North Carolina、美国、27705
        • 招聘中
        • Duke University
        • 首席研究员:
          • Lake Morrison, MD
        • 接触:
      • Greensboro、North Carolina、美国、27403
        • 招聘中
        • Pulmonix LLC
        • 首席研究员:
          • Murali Ramaswamy, MD
        • 接触:
      • Wilmington、North Carolina、美国、28401
        • 终止
        • PMG Research
      • Winston-Salem、North Carolina、美国、27157
        • 招聘中
        • Wake Forest Baptist Health
        • 接触:
        • 首席研究员:
          • Andrew Namen, MD
    • Ohio
      • Cincinnati、Ohio、美国、45267
        • 主动,不招人
        • University of Cincinnati Medical Center
      • Cleveland、Ohio、美国、44195
        • 招聘中
        • Cleveland Clinic
        • 首席研究员:
          • Brian Southern, MD
        • 接触:
      • Columbus、Ohio、美国、43210
        • 招聘中
        • The Ohio State University
        • 接触:
        • 首席研究员:
          • John Odackal
    • Oklahoma
      • Oklahoma City、Oklahoma、美国、73104
        • 招聘中
        • University of Oklahoma
        • 首席研究员:
          • Jad Kebbe, MD
        • 接触:
    • Oregon
      • Portland、Oregon、美国、97220
        • 招聘中
        • Oregon Clinic
        • 首席研究员:
          • David Hotchkin, MD
        • 接触:
    • Pennsylvania
      • Hershey、Pennsylvania、美国、17033
        • 招聘中
        • Penn State College of Medicine - Hershey
        • 首席研究员:
          • Rebecca Bascom, MD
        • 接触:
      • Philadelphia、Pennsylvania、美国、19140
      • Philadelphia、Pennsylvania、美国、19144
    • South Carolina
      • Charleston、South Carolina、美国、29425
        • 招聘中
        • Medical University of South Carolina
        • 首席研究员:
          • Timothy Whelan, MD
        • 接触:
    • Tennessee
      • Nashville、Tennessee、美国、37232
        • 招聘中
        • Vanderbilt University
        • 接触:
        • 首席研究员:
          • Justin Hewlett, MD
    • Texas
      • Dallas、Texas、美国、75235
        • 招聘中
        • University of Texas Southwestern
        • 首席研究员:
          • John Fitzgerald, MD
        • 接触:
      • Dallas、Texas、美国、75246
        • 招聘中
        • Baylor University Medical Center at Dallas
        • 首席研究员:
          • Yolanda Mageto, MD
        • 接触:
      • Houston、Texas、美国、77030
        • 招聘中
        • Baylor College of Medicine
        • 首席研究员:
          • Ivan Rosas, MD
        • 接触:
      • Houston、Texas、美国、77030
      • Houston、Texas、美国、77030
        • 招聘中
        • The University of Texas Health Science Center At Houston
        • 首席研究员:
          • Rodeo Abrencillo, MD
        • 接触:
    • Utah
      • Salt Lake City、Utah、美国、84108
        • 招聘中
        • University of Utah
        • 接触:
        • 首席研究员:
          • Mary Beth Langer, MD
      • Salt Lake City、Utah、美国、84111
        • 招聘中
        • Intermountain Health
        • 接触:
        • 首席研究员:
          • Erin Blackstock, MD
    • Vermont
      • Colchester、Vermont、美国、05446
        • 主动,不招人
        • University of Vermont Lung Center
    • Virginia
      • Charlottesville、Virginia、美国、22908
        • 主动,不招人
        • University from Virginia
      • Falls Church、Virginia、美国、22042-3307
        • 招聘中
        • Inova Health Care Services
        • 接触:
        • 首席研究员:
          • Jared Wilkinson, MD
    • Wisconsin
      • Milwaukee、Wisconsin、美国、53226
        • 主动,不招人
        • The Medical College of Wisconsin

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

21年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

取样方法

非概率样本

研究人群

Subjects with a new diagnosis of IPF or a non- IPF chronic fibrosing ILD established at the time of enrollment in the registry are eligible for participation in the IPF-PRO/ILD-PRO registry if the participant meets the selection criteria.

描述

Inclusion Criteria:

  • Willing and able to provide informed consent

  • Established a new diagnosis (within 12 months) of IPF by the enrolling center.

  • Age 21 years or older, or

  • Diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype during the last 24 months by the enrolling center that meets the following criteria:

    • Chronic fibrosing ILD as defined by reticular abnormality with traction bronchiectasis with or without honeycombing confirmed by chest HRCT scan and/or lung biopsy.

    • Progressive phenotype as defined by fulfilling at least one of the criteria below of fibrotic changes (progression set point) within the last 24 months regardless of treatment considered appropriate in individual ILDs (8):

      • decline in FVC % predicted (% pred) based on ≥10% relative decline
      • decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with worsening of respiratory symptoms as assessed by the site investigator
      • decline in FVC % pred based on ≥5 - <10% relative decline in FVC combined with increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator
      • decline in DLCO % pred based on≥ 10% relative decline
      • worsening of respiratory symptoms as well as increasing extent of fibrotic changes on chest imaging (HRCT scan) as assessed by the site investigator independent of FVC change.

The relative decline for FVC % predicted is calculated using the formula:

Relative Decline= (FVC % Pred (Reference)-FVC % Pred (Screening))/(FVC % Pred (Reference))×100%, where FVC % Pred (Reference) is the greatest measurement of FVC % predicted in the 24 months prior to screening and FVC % Pred (Screening) is the measurement of FVC % predicted at screening.

The relative decline for DLCO % predicted is calculated using the formula:

Relative Decline= (DLCO % Pred (Reference)-DLCO % Pred (Screening))/(DLCO % Pred (Reference))×100%, Where DLCO % Pred (Reference) is the greatest measurement of DLCO % Pred in the 24 months prior to screening and DLCO % Pred (Screening) is the measurement of DLCO % Pred at screening

Exclusion Criteria:

  • Malignancy, treated or untreated, other than skin or early -stage prostate cancer, within the past 5 years
  • Currently listed for lung transplantation at the time of enrollment
  • Currently enrolled in an interventional clinical trial at the time of enrollment in this registry
  • For the additional IPF cohort of 1000 individuals, previous enrollment in this registry.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 观测模型:COHORT
  • 时间观点:PROSPECTIVE

队列和干预

团体/队列
Subjects with a new IPF diagnosis

Subjects with a new diagnosis of IPF established at the time of enrollment in the registry

Subjects with a non-IPF ILD diagnosis

Subjects with a diagnosis of a non-IPF ILD of any duration, including, but not limited to Idiopathic Non-Specific Interstitial Pneumonia (iNSIP), Unclassifiable Idiopathic Interstitial Pneumonias (IIPs), Interstitial Pneumonia with Autoimmune Features (IPAF), Autoimmune ILDs such as Rheumatoid Arthritis (RA-ILD) and Systemic Sclerosis (SSc-ILD), Chronic Hypersensitivity Pneumonitis (HP), Sarcoidosis or Exposure-related ILDs such as asbestosis with progressive phenotype

New Subjects with a new IPF diagnosis

Subjects with a new diagnosis of IPF established at the time of enrollment in the registry not previously enrolled in the registry.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Data on natural history of IPF & non-IPF chronic fibrosing ILD
大体时间:End of Study (3 years after last patient will be enrolled)

Characterize and describe the natural history of patients with a recent confirmed diagnosis of IPF, with emphasis on demographics, co-morbidities, medications, and risks for disease progression or death.

End of Study (3 years after last patient will be enrolled)
Data on current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD
大体时间:End of Study (3 years after last patient will be enrolled)

Understand the current practice patterns for diagnosis of IPF & non-IPF chronic fibrosing ILD

End of Study (3 years after last patient will be enrolled)
Data on impact of IPF & non- IPF chronic fibrosing ILD on patient quality of life.
大体时间:End of Study (3 years after last patient will be enrolled)

Describe the impact of IPF & non- IPF chronic fibrosing ILD on patient quality-of-life (QOL).

End of Study (3 years after last patient will be enrolled)
Blood samples for future research.
大体时间:End of Study (3 years after last patient will be enrolled)

Collect longitudinal bio-samples for future research on disease presentation, progression, and subject response to clinical interventions.

End of Study (3 years after last patient will be enrolled)
HRCT images for future research (for non-IPF chronic fibrosing ILD, and new IPF patients cohort)
大体时间:End of Study (3 years after last patient will be enrolled)

Collect longitudinal HRCT images for future research

End of Study (3 years after last patient will be enrolled)

次要结果测量

结果测量
措施说明
大体时间
Data on management practices compared to existing guidelines.
大体时间:End of Study (3 years after last patient will be enrolled)

Compare disease-specific management practices with existing guidelines.

End of Study (3 years after last patient will be enrolled)
Data on center-specific practices on outcomes.
大体时间:End of Study (3 years after last patient will be enrolled)

Determine the influence of center-specific practices on patient outcomes.

End of Study (3 years after last patient will be enrolled)

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Scott Palmer, MD、Duke Clinical Research Institute, Duke University

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

一般刊物

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2014年6月1日

初级完成 (估计的)

2028年1月1日

研究完成 (估计的)

2031年1月1日

研究注册日期

首次提交

2013年7月31日

首先提交符合 QC 标准的

2013年8月1日

首次发布 (估计的)

2013年8月5日

研究记录更新

最后更新发布 (实际的)

2026年11月12日

上次提交的符合 QC 标准的更新

2026年11月9日

最后验证

2026年7月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅